Axogen, Inc. (AXGN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AXGN SEC filings page.
Axogen, Inc. (AXGN) reported $251.2M in revenue over the twelve months to Jun 30, 2026, up 23.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue has expanded rapidly, but margin compression and inventory buildup keep growth from becoming dependable cash generation.
Revenue rose from$159M in FY2023 to$225M in FY2025, while inventory increased from$23.0M to$42.4M . That mismatch helps explain why operating cash flow was only$0.8M in FY2025 despite a net loss of$15.7M : expansion is absorbing cash through working capital rather than funding itself.
Gross margin narrowed from
Leverage eased: debt-to-equity declined from 0.5x in FY2023 to 0.4x in FY2025, indicating expansion has not been financed primarily by heavier balance-sheet leverage. The current ratio reached 5.1x in FY2025, so reported short-term assets materially exceeded current obligations even as operating cash generation remained thin.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Axogen, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Axogen, Inc. has an operating margin of -3.5%, meaning the company loses $3 on every $100 of revenue. This results in a profitability score of 30/100. This is down from -1.8% the prior year.
Axogen, Inc.'s revenue surged 20.2% year-over-year to $225.2M, reflecting rapid business expansion. This strong growth earns a score of 81/100.
Axogen, Inc. carries a low D/E ratio of 0.38, meaning only $0.38 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 65/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.11, Axogen, Inc. holds $5.11 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 92/100.
While Axogen, Inc. generated $812K in operating cash flow, capex of $3.7M consumed most of it, leaving -$2.9M in free cash flow. This results in a low score of 19/100, reflecting heavy capital investment rather than weak cash generation.
Axogen, Inc. posts a -12.2% return on equity (ROE), meaning it loses $12 for every $100 of shareholders' equity. This results in a returns score of 31/100. This is down from -9.6% the prior year.
Axogen, Inc. scores 13.18, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.1B) relative to total liabilities ($92.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Axogen, Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Axogen, Inc. reported a net loss of $15.7M while generating $812K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Axogen, Inc. reported an operating loss of $7.8M against $7.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Axogen, Inc. generated $69.7M in revenue in Q2 2026. This represents an increase of 23.1% from the same quarter a year earlier. Against the prior quarter it is up 13.5%.
Axogen, Inc.'s EBITDA was -$438K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 112.9% from the same quarter a year earlier. Against the prior quarter it is up 64.3%.
Axogen, Inc. reported -$1.5M in net income in Q2 2026. This represents a decrease of 361.8% from the same quarter a year earlier. Against the prior quarter it is up 92.3%.
Axogen, Inc. earned -$0.03 per diluted share (EPS) in Q2 2026. This represents a decrease of 400.0% from the same quarter a year earlier. Against the prior quarter it is up 92.1%.
Cash & Balance Sheet
Axogen, Inc. generated $6.3M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 9.7% from the same quarter a year earlier. Against the prior quarter it is up 617.0%.
Axogen, Inc. held $94.6M in cash against $0 in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Axogen, Inc.'s gross margin was 72.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.
Axogen, Inc.'s operating margin was -3.1% in Q2 2026, reflecting core business profitability. This is down 6.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.5 percentage points.
Axogen, Inc.'s net profit margin was -2.2% in Q2 2026, showing the share of revenue converted to profit. This is down 3.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 29.7 percentage points.
Axogen, Inc.'s ROE was -0.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.4 percentage points.
Capital Allocation
Axogen, Inc. invested $8.6M in research and development in Q2 2026. This represents an increase of 25.3% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.
Axogen, Inc. invested $893K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 23.7% from the same quarter a year earlier. Against the prior quarter it is down 68.0%.
Not reported for Q2 2026.
AXGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.7M+23.1% | $61.5M+26.6% | $59.9M+21.3% | $60.1M+23.5% | $56.7M+18.3% | $48.6M+17.4% | $49.4M+15.1% | $48.6M+17.9% |
| Cost of Revenue | $19.1M+30.1% | $15.3M+12.0% | $15.5M+31.0% | $14.1M+15.4% | $14.6M+16.5% | $13.6M+55.6% | $11.8M+8.5% | $12.2M+27.6% |
| Gross Profit | $50.7M+20.6% | $46.2M+32.2% | $44.4M+18.2% | $46.0M+26.2% | $42.0M+18.9% | $34.9M+7.1% | $37.6M+17.3% | $36.4M+14.9% |
| R&D Expenses | $8.6M+25.3% | $7.5M+23.4% | $12.4M+84.6% | $7.6M+8.1% | $6.9M+2.9% | $6.1M-17.8% | $6.7M-6.6% | $7.0M+4.5% |
| SG&A Expenses | $13.4M+38.4% | $12.9M+36.1% | $14.6M+65.3% | $10.8M0.0% | $9.7M+2.9% | $9.5M-5.0% | $8.8M+11.3% | $10.8M+9.8% |
| Operating Income | -$2.2M-228.9% | -$2.8M-70.5% | -$9.8M-584.5% | $1.9M+705.1% | $1.7M+490.7% | -$1.7M+63.6% | $2.0M+163.1% | -$316K+92.1% |
| EBITDA | -$438K-112.9% | -$1.2M-1932.8% | -$8.3M-336.1% | $3.6M+159.6% | $3.4M+160.2% | $67K+102.2% | $3.5M+297.3% | $1.4M+150.1% |
| Interest Expense | $1K-99.9% | $694K-69.2% | $1.7M-4.7% | $1.8M-7.2% | $2.0M-9.5% | $2.3M-3.3% | $1.8M-2.3% | $1.9M+128.9% |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$1.5M-361.8% | -$19.6M-410.8% | -$13.2M-3023.6% | $708K+138.1% | $579K+130.1% | -$3.8M+42.2% | $450K+111.6% | -$1.9M+54.6% |
| EPS (Basic) | -$0.03-400.0% | -$0.38-375.0% | -$0.28-2900.0% | $0.02+150.0% | $0.01+125.0% | -$0.08+46.7% | $0.01+111.1% | -$0.04+60.0% |
| EPS (Diluted) | -$0.03-400.0% | -$0.38-375.0% | -$0.28-2900.0% | $0.01 | $0.01+125.0% | -$0.08+46.7% | $0.01+111.1% | -$0.04+60.0% |
| Diluted Shares (Avg) | 53M+11.2% | 52M+14.1% | N/A | 49M | 48M+9.8% | 45M+4.6% | N/A | 44M+2.0% |
AXGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $304.9M+48.4% | $289.5M+47.6% | $221.7M+8.8% | $216.4M+12.7% | $205.5M+8.7% | $196.2M+5.2% | $203.7M+3.5% | $192.0M-1.4% |
| Current Assets | $200.4M+93.8% | $184.7M+98.5% | $120.4M+21.4% | $114.5M+32.7% | $103.4M+25.7% | $93.1M+18.3% | $99.2M+12.7% | $86.3M-1.4% |
| Cash & Equivalents | $94.6M+372.0% | $82.7M+356.8% | $35.5M+29.0% | $23.9M+28.1% | $20.0M+4.4% | $18.1M+15.2% | $27.6M-11.2% | $18.7M-40.0% |
| Short-Term Investments | $16.8M+70.3% | $18.9M+376.9% | $6.0M+0.9% | $11.9M+102.6% | $9.9M+408.5% | $4.0M+106.8% | $5.9M | $5.9M+292.8% |
| Inventory | $47.3M+28.7% | $46.1M+29.8% | $42.4M+27.7% | $40.6M+38.2% | $36.8M+31.3% | $35.5M+28.5% | $33.2M+44.1% | $29.4M+27.6% |
| Accounts Receivable | $34.1M+21.8% | $28.3M+7.7% | $26.2M+8.6% | $30.8M+25.0% | $28.0M+11.4% | $26.3M+8.6% | $24.1M-4.1% | $24.6M+5.9% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $48.6M-47.8% | $44.7M-50.8% | $92.8M-7.0% | $95.6M+3.3% | $93.2M-0.1% | $90.8M-2.7% | $99.8M-1.3% | $92.6M-4.4% |
| Current Liabilities | $30.4M+21.6% | $26.0M+19.6% | $23.6M-23.0% | $28.0M+21.6% | $25.0M+6.7% | $21.7M-5.2% | $30.6M+0.6% | $23.0M-13.6% |
| Non-Current Liabilities | $18.2M-73.3% | $18.7M-73.0% | $69.3M+0.1% | $67.6M-2.8% | $68.2M-2.3% | $69.1M-1.9% | $69.2M-2.2% | $69.5M-0.9% |
| Long-Term Debt | $0-100.0% | $0-100.0% | $48.4M+1.9% | $48.2M+1.9% | $47.9M+1.9% | $47.7M+1.9% | $47.5M+1.9% | $47.3M+1.9% |
| Total Equity | $256.3M+128.2% | $244.8M+132.3% | $128.8M+24.0% | $120.8M+21.5% | $112.3M+17.3% | $105.4M+13.1% | $103.9M+8.6% | $99.4M+1.6% |
| Retained Earnings | -$328.1M-11.4% | -$326.5M-10.7% | -$307.0M-5.4% | -$293.8M-0.7% | -$294.5M-1.6% | -$295.1M-2.5% | -$291.3M-3.5% | -$291.7M-5.2% |
Not reported in any period shown, so not listed: Goodwill.
AXGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.2M-6.6% | $1.6M+111.9% | $3.0M-65.2% | $3.2M-17.4% | $7.7M+85.6% | -$13.2M-7.4% | $8.7M+4239.8% | $3.9M+139.9% |
| Depreciation & Amortization | $1.7M-0.3% | $1.6M-7.2% | $1.6M-0.2% | $1.7M+0.6% | $1.7M-0.6% | $1.7M+13.7% | $1.6M+5.0% | $1.7M+40.4% |
| Stock-Based Compensation | N/A | $6.8M+135.2% | N/A | $5.4M+8.4% | $5.2M+32.3% | $2.9M-25.8% | N/A | $5.0M+5.4% |
| Capital Expenditures | $893K+23.7% | $2.8M+989.5% | $1.2M+86.1% | $1.5M+154.6% | $722K-20.7% | $256K-72.3% | $670K-54.2% | $597K-83.8% |
| Free Cash Flow | $6.3M-9.7% | -$1.2M+90.9% | $1.8M-77.8% | $1.7M-48.5% | $7.0M+115.3% | -$13.4M-1.9% | $8.1M+581.8% | $3.3M+260.1% |
| Investing Cash Flow | $500K+107.2% | -$16.0M-1292.2% | $4.0M+597.2% | -$3.8M+25.0% | -$6.9M-463.4% | $1.3M+141.2% | -$813K-193.5% | -$5.0M-183.4% |
| Financing Cash Flow | $4.2M+262.7% | $59.5M+2398.1% | $4.6M+370.7% | $2.4M+318.5% | $1.2M+112.7% | $2.4M+1067.6% | $970K+132.1% | $572K+11340.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
AXGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.7%-1.5pp | 75.2%+3.2pp | 74.1%-1.9pp | 76.5%+1.6pp | 74.2%+0.4pp | 71.9%-6.9pp | 76.0%+1.4pp | 74.9%-1.9pp |
| Operating Margin | -3.1%-6.0pp | -4.6%-1.2pp | -16.3%-20.4pp | 3.2%+3.8pp | 2.9%+3.8pp | -3.4%+7.6pp | 4.1%+11.5pp | -0.7%+9.1pp |
| Net Margin | -2.2%-3.2pp | -31.9%-24.0pp | -22.0%-22.9pp | 1.2%+5.0pp | 1.0%+5.0pp | -7.9%+8.1pp | 0.9%+10.0pp | -3.8%+6.1pp |
| Return on Equity | -0.6%-1.1pp | -8.0%-4.4pp | -10.2%-10.6pp | 0.6%+2.5pp | 0.5%+2.5pp | -3.6%+3.5pp | 0.4%+4.5pp | -1.9%+2.3pp |
| Return on Assets | -0.5%-0.8pp | -6.8%-4.8pp | -5.9%-6.2pp | 0.3%+1.3pp | 0.3%+1.3pp | -1.9%+1.6pp | 0.2%+2.2pp | -1.0%+1.1pp |
| Current Ratio | 6.60+2.5x | 7.10+2.8x | 5.11+1.9x | 4.09+0.3x | 4.14+0.6x | 4.28+0.8x | 3.24+0.3x | 3.74+0.5x |
| Debt-to-Equity | 0.00-0.4x | 0.00-0.5x | 0.38-0.1x | 0.40-0.1x | 0.43-0.1x | 0.450.0x | 0.460.0x | 0.480.0x |
| Asset Turnover | 0.230.0x | 0.210.0x | 0.270.0x | 0.280.0x | 0.280.0x | 0.250.0x | 0.240.0x | 0.250.0x |
| FCF Margin | 9.1%-3.3pp | -2.0%+25.7pp | 3.0%-13.3pp | 2.8%-4.0pp | 12.4%+5.6pp | -27.7%+4.2pp | 16.3%+20.2pp | 6.8%+11.8pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Axogen, Inc. AXGN | FY2025 | $225.2M | -$15.7M | -7.0% | $2.1B | 53/100 |
| SI-BONE, Inc. SIBN | FY2025 | $200.9M | -$18.9M | -9.4% | $868.1M | 53/100 |
| Tandem Diabetes Care, Inc. TNDM | FY2025 | $1.0B | -$204.7M | -20.2% | $1.1B | 40/100 |
| iRadimed Corporation IRMD | FY2025 | $83.8M | $22.5M | 26.8% | $1.1B | 86/100 |
| Orthofix Medical Inc. OFIX | FY2025 | $822.3M | -$92.2M | -11.2% | $373.5M | 43/100 |
| Avanos Medical, Inc. AVNS | FY2025 | $701.2M | -$72.9M | -10.4% | $1.2B | 44/100 |
Where Axogen, Inc. Ranks
Frequently Asked Questions
What is Axogen, Inc.'s annual revenue?
Axogen, Inc. (AXGN) reported $225.2M in total revenue for fiscal year 2025. This represents a 20.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Axogen, Inc.'s revenue growing?
Axogen, Inc. (AXGN) revenue grew by 20.2% year-over-year, from $187.3M to $225.2M in fiscal year 2025.
Is Axogen, Inc. profitable?
No, Axogen, Inc. (AXGN) reported a net income of -$15.7M in fiscal year 2025, with a net profit margin of -7.0%.
What is Axogen, Inc.'s EBITDA?
Axogen, Inc. (AXGN) had EBITDA of -$1.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Axogen, Inc. have?
As of fiscal year 2025, Axogen, Inc. (AXGN) had $35.5M in cash and equivalents against $48.4M in long-term debt.
What is Axogen, Inc.'s gross margin?
Axogen, Inc. (AXGN) had a gross margin of 74.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Axogen, Inc.'s operating margin?
Axogen, Inc. (AXGN) had an operating margin of -3.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Axogen, Inc.'s net profit margin?
Axogen, Inc. (AXGN) had a net profit margin of -7.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Axogen, Inc.'s return on equity (ROE)?
Axogen, Inc. (AXGN) has a return on equity of -12.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Axogen, Inc.'s free cash flow?
Axogen, Inc. (AXGN) recorded an outflow of $2.9M in free cash flow during fiscal year 2025. This represents a -304.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Axogen, Inc.'s operating cash flow?
Axogen, Inc. (AXGN) generated $812K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Axogen, Inc.'s total assets?
Axogen, Inc. (AXGN) had $221.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Axogen, Inc.'s capital expenditures?
Axogen, Inc. (AXGN) invested $3.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Axogen, Inc. spend on research and development?
Axogen, Inc. (AXGN) invested $32.9M in research and development during fiscal year 2025.
What is Axogen, Inc.'s current ratio?
Axogen, Inc. (AXGN) had a current ratio of 5.11 as of fiscal year 2025, which is generally considered healthy.
What is Axogen, Inc.'s debt-to-equity ratio?
Axogen, Inc. (AXGN) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Axogen, Inc.'s return on assets (ROA)?
Axogen, Inc. (AXGN) had a return on assets of -7.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Axogen, Inc.'s P/E ratio?
Axogen, Inc. (AXGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.1B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Axogen, Inc.'s price-to-sales ratio?
Axogen, Inc. (AXGN) trades at 8.4x sales, its market capitalization divided by revenue of $251.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.1B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Axogen, Inc.'s Altman Z-Score?
Axogen, Inc. (AXGN) has an Altman Z-Score of 13.18, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Axogen, Inc.'s Piotroski F-Score?
Axogen, Inc. (AXGN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Axogen, Inc.'s earnings high quality?
Axogen, Inc. (AXGN) reported a net loss of $15.7M while generating $812K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Axogen, Inc. cover its interest payments?
Axogen, Inc. (AXGN) reported an operating loss of $7.8M against $7.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Axogen, Inc.?
Axogen, Inc. (AXGN) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.